Arbutus Biopharma

Update in progress

ABUS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company in the United States focused on infectious diseases. Its hepatitis B program includes Imdusiran, a subcutaneously delivered RNAi therapy (GalNAc) in Phase 2a that aims to suppress all HBV antigens including HBsAg, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b that may boost HBV-specific immunity. It licenses LNP tech from Alnylam. Formerly Tekmira, it was renamed in 2015 and is based in Warminster, PA.

Company score

Sentiment: -0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.52; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive